Exagen Inc. (XGN)

NASDAQ: XGN · Real-Time Price · USD
8.91
+0.04 (0.45%)
At close: Aug 6, 2025, 4:00 PM
9.08
+0.17 (1.91%)
After-hours: Aug 6, 2025, 4:37 PM EDT
0.45%
Market Cap196.05M
Revenue (ttm)58.86M
Net Income (ttm)-16.98M
Shares Out 22.00M
EPS (ttm)-0.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133,909
Open8.91
Previous Close8.87
Day's Range8.48 - 9.00
52-Week Range2.24 - 9.10
Beta1.62
AnalystsStrong Buy
Price Target11.75 (+31.87%)
Earnings DateJul 29, 2025

About AZPN

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and ot... [Read more]

Sector Healthcare
IPO Date Sep 19, 2019
Employees 215
Stock Exchange NASDAQ
Ticker Symbol XGN
Full Company Profile

Financial Performance

In 2024, Exagen's revenue was $55.64 million, an increase of 5.89% compared to the previous year's $52.55 million. Losses were -$15.12 million, -36.19% less than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $11.75, which is an increase of 31.87% from the latest price.

Price Target
$11.75
(31.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Exagen Inc. to Participate in Third Quarter Investor Conferences

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following up...

6 hours ago - GlobeNewsWire

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

Exagen Inc. (NASDAQ:XGN) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Dougl...

8 days ago - Seeking Alpha

Exagen Inc. Reports Strong Q2 2025 Results

CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025,...

8 days ago - GlobeNewsWire

Exagen Inc. Appoints Chas McKhann to Board of Directors

CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Boa...

20 days ago - GlobeNewsWire

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, ...

22 days ago - GlobeNewsWire

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chie...

6 weeks ago - GlobeNewsWire

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,50...

3 months ago - GlobeNewsWire

Exagen Inc. Prices Public Offering of Common Stock

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten p...

3 months ago - GlobeNewsWire

Exagen Inc. Announces Proposed Public Offering of Common Stock

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering ...

3 months ago - GlobeNewsWire

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - ...

3 months ago - Seeking Alpha

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025,...

3 months ago - GlobeNewsWire

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) --...

3 months ago - GlobeNewsWire

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's ...

3 months ago - Seeking Alpha

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before th...

3 months ago - GlobeNewsWire

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Exagen Inc. (NASDAQ:XGN) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black ...

5 months ago - Seeking Alpha

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility ...

5 months ago - GlobeNewsWire

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024...

5 months ago - GlobeNewsWire

Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming inve...

6 months ago - GlobeNewsWire

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBI...

7 months ago - GlobeNewsWire

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVI...

8 months ago - GlobeNewsWire

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diag...

9 months ago - GlobeNewsWire

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Exagen, Inc. (NASDAQ:XGN) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Partic...

9 months ago - Seeking Alpha

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College o...

10 months ago - GlobeNewsWire

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthca...

1 year ago - GlobeNewsWire

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Exagen, Inc. (NASDAQ:XGN) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Ryan Douglas - IR John Aballi - President & CEO Conference Call Participants Kyle Mikson - Ca...

1 year ago - Seeking Alpha